

Resource Summary Report

Generated by [RRID](#) on Aug 3, 2026

Cytokeratin, pan Antibody (AE-1/AE-3) [Alexa Fluor® 488]

RRID:AB_3284601

Type: Antibody

Proper Citation

Novus Cat# NBP2-33200AF488, RRID:AB_3284601

Antibody Information

URL: http://antibodyregistry.org/AB_3284601

Proper Citation: Novus Cat# NBP2-33200AF488, RRID:AB_3284601

Target Antigen: Cytokeratin, pan

Host Organism: Mouse

Clonality: monoclonal

Comments: Applications: Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Flow (Intracellular), CyTOF-ready, Single Cell Western, Dual RNAscope ISH-IHC

Antibody Name: Cytokeratin, pan Antibody (AE-1/AE-3) [Alexa Fluor® 488]

Description: This monoclonal targets Cytokeratin, pan

Target Organism: Human, Rat, Bovine, Monkey, Rabbit, Zebrafish, Canine, Reptile, Mouse, Chicken

Clone ID: AE-1/AE-3

Antibody ID: AB_3284601

Vendor: Novus

Catalog Number: NBP2-33200AF488

Record Creation Time: 20250820T064422+0000

Record Last Update: 20250821T004855+0000

Ratings and Alerts

No rating or validation information has been found for Cytokeratin, pan Antibody (AE-1/AE-3) [Alexa Fluor® 488].

No alerts have been found for Cytokeratin, pan Antibody (AE-1/AE-3) [Alexa Fluor® 488].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Colevas AD, et al. (2025) First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr-Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 815.

Burns GW, et al. (2025) Spatial transcriptomic analysis identifies epithelium-macrophage crosstalk in endometriotic lesions. *iScience*, 28(2), 111790.

Kennedy JC, et al. (2025) A progranulin variant causing childhood interstitial lung disease responsive to anti-TNF-? biologic therapy. *Med (New York, N.Y.)*, 6(6), 100607.